J.P. Morgan Extras: Pandemic Impact on Launch, Production, Development And More
Updates From Lilly, Takeda, Amgen, Horizon, Berkeley Lights
Executive Summary
Additional views from the virtual J.P. Morgan Healthcare Conference on ways the COVID-19 pandemic has affected business practices and lessons learned for the future.
You may also be interested in...
With Return Of Tepezza Supply, Horizon Is Ready To Get Back To Business
US FDA approved new manufacturing for Tepezza, which had been sidelined by COVID-19 vaccine production. Horizon said it will resupply the market in April.
Horizon's Tepezza Broke The Mold For 2020 Launches, But Still Got Snared By COVID-19
Tepezza was the breakout launch of the year and will change Horizon's growth trajectory, but for now it has been sidelined by a supply constraint caused by COVID-19 vaccine manufacturing.
Pandemic Perspectives: COVID-19 Upended Drug Launches In Ways That Will Stick
Preliminary data from IQVIA suggest 2020 was one of the weakest in recent years for new launch trajectories although drug companies tell Scrip there are some lessons learned from promoting during the pandemic.